BMS expands r&d base in India
Bristol-Myers Squibb (BMS) is expanding its r&d capabilities in India by increasing the scope of its existing relationship with the Bangalore-based biopharamceutials developer Biocon.
Bristol-Myers Squibb (BMS) is expanding its r&d capabilities in India by increasing the scope of its existing relationship with the Bangalore-based biopharamceutials developer Biocon.
Biocon will, through its subsidiary Syngene International, establish a research facility in Bangalore that could ultimately house more than 400 scientists to help advance BMS's discovery and early drug development.
In a separate multi-year agreement, BMS will expand its relationship with consultancy and outsourcing company Accenture to include support for clinical data and document management, pharmacovigilance, and scientific writing functions in India.
Accenture will also provide maintenance and support for r&d information systems. BMS will use Accenture's Life Science Centres for Excellence in Bangalore and Chennai, which follow industry accepted operational practices and international standards in the clinical area.
"This broad expansion of r&d in India will allow us to grow competitively while maintaining our industry-leading position in productivity and innovation," said Elliott Sigal, executive vice-president, BMS, and chief scientific officer, president, Pharmaceutical Research Institute.
Representatives from Bristol-Myers Squibb and Biocon will hold a groundbreaking ceremony of the new research facility at Biocon Park in Bangalore on Wednesday, March 21.